Amicus Therapeutics, Inc. - Common Stock (NQ:FOLD)

14.49 UNCHANGED

Last Price Updated: 4:00 PM EDT, Apr 24, 2026 Add to My Watchlist

Quote

Overview Detailed Quote Charting Historical Prices

News

All News News Headlines Press Releases

Research

Quarterly Reports Insider Filings Other Filings

Headline News about Amicus Therapeutics, Inc. - Common Stock

< Previous 1 2 3 4 Next >

CIBRA Capital Buys Stake in Allied Gold Stock ↗

April 27, 2026

Allied Gold Corporation operates a diversified mining business with core assets across Africa, producing and selling gold and silver.

Via The Motley Fool

Topics Regulatory Compliance

CIBRA Capital Makes a Big Merger Arbitrage Bet On Amicus Therapeutics (FOLD) ↗

April 25, 2026

Amicus Therapeutics targets rare genetic diseases with proprietary therapies and a pipeline of treatments for underserved patient groups.

Via The Motley Fool

Topics Regulatory Compliance

Rice Hall James Buys QuidelOrtho Stock ↗

March 09, 2026

QuidelOrtho develops diagnostic technologies for healthcare providers worldwide, spanning labs, clinics, and retail settings.

Via The Motley Fool

Topics Regulatory Compliance

Amicus Stock Surges To Near 2-Year Highs On BioMarin's $4.8B Buyout Deal ↗

December 19, 2025

Via Stocktwits

Earnings Scheduled For November 4, 2025 ↗

November 04, 2025

Via Benzinga

Earnings Scheduled For July 31, 2025 ↗

July 31, 2025

Via Benzinga

Earnings Scheduled For May 1, 2025 ↗

May 01, 2025

Via Benzinga

Rice Hall James Buys Stride Stock ↗

March 09, 2026

Stride delivers online and blended education solutions for K-12, career, and adult learners through proprietary technology platforms.

Via The Motley Fool

Investment Manager Bets Big on PTCT Stock, Adds 41,000 Shares, According to Recent SEC Filing ↗

March 03, 2026

PTC Therapeutics develops therapies for rare diseases, with a portfolio spanning commercial products and investigational candidates.

Via The Motley Fool

Topics Regulatory Compliance

Investment Firm Adds Nearly $4 Milllion Worth of DYN Shares, According to Recent SEC Filing ↗

March 02, 2026

This clinical-stage biotech develops therapies for rare muscle diseases using its proprietary FORCE platform and research-driven approach.

Via The Motley Fool

Topics Regulatory Compliance

Investment Advisor Bets Big on CMPX Stock, Adds 2.5 Million Shares, According to Latest SEC Filing ↗

March 02, 2026

This clinical-stage biotech develops antibody therapeutics targeting cancer, with a pipeline focused on oncology and immunotherapy markets.

Via The Motley Fool

Topics Regulatory Compliance

Should You Buy BioMarin Pharmaceutical Before Feb. 18? ↗

January 31, 2026

There's no need to hurry in buying this biotech stock.

Via The Motley Fool

Topics Earnings

The Great Unlocking: 2026 Opens with a Historic Surge in Large-Cap M&A Activity

January 06, 2026

The first week of 2026 has signaled a tectonic shift in the global financial landscape, as a wave of multi-billion dollar acquisitions has effectively ended the deal-making drought of the previous two...

Via MarketMinute

Topics Artificial Intelligence Economy Energy

BioMarin’s $4.8 Billion Amicus Acquisition: A Strategic Pivot to Rare Disease Dominance

January 02, 2026

In a move that has sent shockwaves through the biotechnology sector, BioMarin Pharmaceutical Inc. (Nasdaq: BMRN) announced on December 19, 2025, that it has entered into a definitive agreement to...

Via MarketMinute

Topics Economy Intellectual Property

Biopharma’s Year-End Rollercoaster: Mereo Plummets 90% as BioMarin Seals $4.8 Billion Amicus Deal

December 29, 2025

The biopharmaceutical sector witnessed a dramatic surge in volatility today, December 29, 2025, as the industry careened toward the end of its strongest year in two decades. In a day defined by extreme...

Via MarketMinute

Topics ETFs Intellectual Property

The Liquidity Vacuum: Thin Holiday Trading Sparks Volatility as 2025 Draws to a Close

December 26, 2025

As the final week of 2025 unfolds, the hallowed halls of the New York Stock Exchange and the digital corridors of the Nasdaq have transformed into a "ghost town." With many institutional traders having...

Via MarketMinute

Topics Artificial Intelligence ETFs Economy

Unusual volume stocks in Tuesday's session ↗

December 23, 2025

Let's explore the current happenings on the US markets on Tuesday. Below, you'll find the stocks exhibiting unusual volume in today's session.

Via Chartmill

Let's have a look at the top gainers and losers one hour before the close of the markets of today's session. ↗

December 19, 2025

Let's have a look at what is happening on the US markets one hour before the close of the markets on Friday. Below you can find the top gainers and losers in today's session.

Via Chartmill

Discover the most active stocks in Friday's session. ↗

December 19, 2025

Let's have a look at what is happening on the US markets on Friday. Below you can find the most active stocks in today's session.

Via Chartmill

Which stocks are moving on Friday? ↗

December 19, 2025

Keep an eye on the top gainers and losers in Friday's session, as they reflect the most notable price movements.

Via Chartmill

Which stocks are gapping on Friday? ↗

December 19, 2025

Investors and traders are closely monitoring the gap up and gap down stocks in today's session on Friday. Let's explore the market movements and identify the stocks with significant gaps.

Via Chartmill

Discover the top movers in Friday's pre-market session. ↗

December 19, 2025

Before the US market kicks off on Friday, let's examine the pre-market session and unveil the notable performers among the top gainers and losers.

Via Chartmill

Healthcare Investor Exits $13 Million Stake STAAR Surgical Stake as Alcon Deal Drama Looms ↗

December 03, 2025

One specialist investor just walked away from STAAR Surgical entirely—right as uncertainty over a delayed Alcon deal looms.

Via The Motley Fool

Topics Regulatory Compliance

PTC Therapeutics Swings to a Profit on $211 Million in Revenue — Is This Why a Major Fund Just Invested $32 Million? ↗

December 03, 2025

PTC’s turnaround quarter is raising eyebrows—here’s why one major investor just doubled down.

Via The Motley Fool

Topics Regulatory Compliance

Dyne Therapeutics Stock Down 30% in a Year — So Why Did One Investor Add Nearly 1 Million Shares? ↗

December 03, 2025

Dyne Therapeutics Stock Down 30% in a Year — So Why Did One Investor Add Nearly 1 Million Shares?

Via The Motley Fool

Topics Regulatory Compliance

Amicus Therapeutics Inc (NASDAQ:FOLD) Q3 2025 Earnings: A Landmark Quarter with Strong Profitability Beat ↗

November 04, 2025

Amicus Therapeutics (FOLD) beats Q3 2025 earnings estimates with strong revenue growth and a major milestone in profitability, driving positive market momentum.

Via Chartmill

This CSX Analyst Turns Bullish; Here Are Top 5 Upgrades For Thursday ↗

September 18, 2025

Via Benzinga

Amicus (FOLD) Q2 Revenue Jumps 22% ↗

August 01, 2025

Via The Motley Fool

Topics Intellectual Property

Amicus Therapeutics Inc (NASDAQ:FOLD) Beats Q2 2025 Earnings and Revenue Estimates, Shares Rise in Pre-Market Trading ↗

July 31, 2025

Amicus Therapeutics (FOLD) beats Q2 2025 revenue and EPS estimates, driven by strong growth in Galafold and Pompe disease therapies, sparking a 2.77% pre-market rally.

Via Chartmill

12 Health Care Stocks Moving In Thursday's Pre-Market Session ↗

May 01, 2025

Via Benzinga

< Previous 1 2 3 4 Next >

Stock Quote API & Stock News API supplied by www.cloudquote.io. Quotes delayed at least 20 minutes. Market data may be delayed. Research information, not personalized advice.